Stemedica Cell Technologiesincis A Clinical Stage Biopharmaceutical Company Focused On The Development And Commercialization Of Progenitor Cell And Protein Therapeutics For Underserved Medical Conditionsstemedica Has Developed A Proprietary Manufacturing Technology Platform That Produces Allogeneic Progenitor Cell Products With Intellectual Property Protection Under A Low Oxygenlow Tension Environment In A Cgmp Compliant Manufacturing Facilitythe Company S Lead Drug Candidateischemia Tolerant Mesenchymal Stem Cellsor Itmscsis An Allogeneic Progenitor Cell Therapy Currently In Clinical Development For The Treatment Of Ischemic Stroke And Alzheimer S Diseasethe Company S Second Drug Candidateischemia Tolerant Neural Progenitor Cellsor Itnscsis An Allogeneic Cell Therapy Currently In Development For Spinal Cord Injuryin Additionstemedica Is Developing Progenitor Multi Cell Therapyitmscs And Itnscsfor Ischemic Stroke And Progenitor Cell And Protein Combination Therapy For Alzheimer S Diseasemore Information On Stemedica May Be Found At Www Stemedica Com
